Updated COVID-19 Vaccines to Include Children Ages 6 Mos – 5 Yrs.

Translate to Spanish or other 102 languages!

CDC expanded the use of updated (bivalent) COVID-19 vaccines for children ages 6 months through 5 years. mage for illustration purposes
CDC expanded the use of updated (bivalent) COVID-19 vaccines for children ages 6 months through 5 years. mage for illustration purposes

Mega Doctor News

- Advertisement -

CDC expanded the use of updated (bivalent) COVID-19 vaccines for children ages 6 months through 5 years. Children ages 6 months through 5 years who previously completed a Moderna primary series are eligible to receive a Moderna bivalent booster 2 months after their final primary series dose. Children ages 6 months through 4 years who are currently completing a Pfizer primary series will receive a Pfizer bivalent vaccine as their third primary dose.

Updated COVID-19 vaccines are formulated to protect against some of the more recently circulating viruses.

Most importantly, COVID-19 vaccines are critical to providing ongoing protection as immunity wanes and the virus continues to mutate.

- Advertisement -

The vast majority of children in this age group have not received any doses of a COVID-19 vaccine. CDC is working to increase parent and provider confidence in COVID-19 vaccines and improve uptake among the 95% of children who are not vaccinated or who have not completed the COVID-19 vaccine primary series. Parents should talk to their child’s health care provider to ensure their child is up to date on their COVID-19 and other vaccines.

Information Source: CDC

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

$281 Million Unlocked to Bridge the Gap in Rural Medical Access

AUSTIN - Governor Greg Abbott announced the Texas Health and Human Services Commission (HHSC) will receive $281 million in federal funding for the second year of Rural Texas Strong, a five-year initiative to improve rural healthcare throughout the state.

Skin Myths Dermatologists Want You to Stop Believing Immediately

Have you ever wondered what a dermatologist's top skincare recommendations are

FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk 

The U.S. Food and Drug Administration today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke (a stroke caused by a clot that did not originate in the heart) or a high-risk transient ischemic attack (TIA), often called a “mini-stroke.” 

Practical Health Tips to Navigate Cold and Flu Season Safely

With cold and flu season in full swing, experts say there are some simple steps you can take to protect yourself and those around you.
- Advertisement -